Changes in Hong Kong stocks | Lepu Biotech (02157) rose nearly 4% CMG901 achieved positive top-line results in the global phase III clinical trial CLARITY-GASTRIC01

The Zhitong Finance App learned that Lepu Biotech (02157) rose nearly 4% and had an increase of more than 12% in early trading. As of press release, it rose 3.83% to HK$4.61, with a turnover of HK$91.6484 million.

According to the news, on July 28, Lepu Biotech announced the latest status of cooperation between the Group and AstraZeneca AB (AstraZeneca, a global biopharmaceutical company) on the antibody-conjugated drug (ADC) candidate CMG901 (sonesitatug vedotin, also known as AZD0901). According to reports, in February 2023, KYM Biosciences Inc. (KYM, a joint venture established by the company and Connoya Biomedical Technology Co., Ltd. (Connoya)) and AstraZeneca signed an exclusive global licensing agreement to develop and commercialize CMG901 (drug candidate jointly developed by the company and Conocia through KYM).

As of the date of this announcement, positive top-line results of the Clarity-gastric01 global phase III clinical trial showed that compared with the treatment options selected by the researchers, sonesitatug vedotin showed statistically significant and clinically significant overall survival (OS) improvements in second-line and later-line (2L+) Claudin 18.2 positive advanced gastric cancer patients.